KRYS
Krystal Biotech, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 4 ▲ Krystal Biotech reported strong Q1 2026 results with VYJUVEK revenue…
- Jun 25 ▼ 1 insider sell $347.3K at $347.27
- Aug 3 ▲ Krystal Biotech reported Q2 2026 VYJUVEK revenue of $119.2M (+24% Yo…
- Aug 14 RBC Capital initiates
- Aug 14 ▼ 1 insider sell $8.2M at $329.12
- Sep 4 ▼ 2 insiders sell $18.0M at $359.32
- Sep 30 ▲ 3 funds open new positions (13F)
- Oct 15 ▲ Krystal Biotech announced positive proof-of-concept clinical data fo…
- Nov 2 ▲ Krystal Biotech reported Q3 2026 VYJUVEK revenue of $127.3M, up 30%…
- Nov 2 ▲ Earnings: KRYS Q3 2026 Earnings: EPS $2.05 (+13.5% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $26.5M.
- InstitutionsBULLISH
Q3 2026: 44 added (3 new), 20 trimmed or exited. Largest new: Clearbridge Investments $12.5M, Quadrature Capital $10.8M.
- AnalystsBULLISH
18 of 20 rate it Buy or better. Median target $380.00 (+24%).
- EstimatesRISING
Current-quarter EPS estimate $2.149 → $2.221 over 90 days. 1 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest +3.7% to 3.04M shares. 12.2 days to cover, ≈10.3% of shares.
- TrendDOWNTREND
7% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 4.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FRANKLIN TEMPLETON INC | ADD | $115.3M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | ADD | $56.9M |
| JPMORGAN CHASE & CO | ADD | $56.6M |
| MORGAN STANLEY | TRIM | $53.3M |
| PRINCIPAL FINANCIAL GROUP INC | TRIM | $41.8M |
| UBS Group AG | TRIM | $35.2M |
| RHUMBLINE ADVISERS | ADD | $26.5M |
| CONGRESS ASSET MANAGEMENT CO | ADD | $18.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
20 analystsPrice is inside the target range. Median implies +24%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 3, 2026 | Citigroup MAINTAIN | Buy |
| Nov 3, 2026 | TD Cowen MAINTAIN | Buy |
| Nov 3, 2026 | RBC Capital MAINTAIN | Outperform |
| Oct 15, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 21, 2026 | B of A Securities MAINTAIN | Buy |
| Aug 14, 2026 | RBC Capital INITIATE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
ROSSI DINO A Director Nov 12, 2026 | GIFT | 3,500 sh |
Gangolli Julian S Director Sep 14, 2026 | AWARD | 1,187 sh |
Gangolli Julian S Director Sep 14, 2026 | AWARD | 471 sh |
JANNEY DANIEL Director Sep 14, 2026 | AWARD | 1,187 sh |
Mason Christopher Director Sep 14, 2026 | AWARD | 1,187 sh |
JANNEY DANIEL Director Sep 14, 2026 | AWARD | 471 sh |
Mason Christopher Director Sep 14, 2026 | AWARD | 471 sh |
Sutherland Everett Rand Director Sep 14, 2026 | AWARD | 471 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $2.22 | $1.79–$4.06 | -0.7% | $134.5M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
18 filings · 6 bullish · 2 bearish · 10 neutral- BULLISH 8-KNov 2, 2026
Krystal Biotech reported Q3 2026 VYJUVEK revenue of $127.3M, up 30% YoY, above the $126.5M…
The revenue beat and narrowed expense guidance signal operational leverage. The $400M buyback (about 4% of market cap) adds a capital return element. Watch for KB803 IOLITE top-line results in…
- BULLISH PRESS-RELEASENov 2, 2026
Krystal Biotech reported Q3 2026 VYJUVEK revenue of $127.3M, up 30% YoY and above the $126.5M…
Monitor upcoming clinical catalysts: KB111 interim HHD data before year-end, KB803 top-line results in February 2027, and KB801 NK trial enrollment progress. The $400M buyback authorization provides…
- BEARISH SC 13G/AOct 30, 2026
Vanguard Portfolio Management LLC filed an amended Schedule 13G for Krystal Biotech, reporting…
Vanguard's reduction below 5% removes a major passive holder from the 5%+ ownership list. Monitor for further institutional selling and any impact on stock liquidity.
- BULLISH INST-CLUSTEROct 27, 2026
In Q2 2026, 35 institutional investors accumulated $137.4M in Krystal Biotech shares while 15…
The cluster shows strong institutional accumulation, but the 45-day reporting lag and absence of insider buying suggest caution. Monitor upcoming 13F filings and any insider Form 4 activity to…
All KRYS filing & press-release reports (18)
- 8-K reportNov 2, 2026
- PRESS-RELEASE reportNov 2, 2026
- SC 13G/A reportOct 30, 2026
- INST-CLUSTER reportOct 27, 2026
- SC 13G/A reportOct 27, 2026
- PRESS-RELEASE reportOct 22, 2026
- INST-CLUSTER reportOct 21, 2026
- 8-K reportOct 15, 2026
- CLUSTER reportSep 4, 2026
- 144 reportAug 14, 2026
- 8-K reportAug 3, 2026
- PRESS-RELEASE reportJul 23, 2026
- CLUSTER reportJun 5, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportApr 21, 2026
- DEFA14A reportApr 3, 2026
- CLUSTER reportFeb 27, 2026
- CLUSTER reportFeb 27, 2026